Autonomix Medical, Inc. (NASDAQ: AMIX) shares were little changed Thursday, as the Woodlands, Texas-based medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, CEO Brad Hauser addressed Pain Awareness Month and what the Company is doing to address the significant unmet need in pancreatic cancer pain.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies.
“We believe,” read this morning’s news release, “this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
“Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.”
AMIX shares inched up 0.2 cents to 58 cents.
